Get the Stockscreener App
4.76
2.26%
-0.11
After Hours:
4.71
-0.05
-1.05%
Opus Genetics Inc stock is traded at $4.76, with a volume of 1.24M.
It is down -2.26% in the last 24 hours and up +15.82% over the past month.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
See More
Previous Close:
$4.87
Open:
$4.89
24h Volume:
1.24M
Relative Volume:
0.54
Market Cap:
$396.01M
Revenue:
$14.20M
Net Income/Loss:
$-49.59M
P/E Ratio:
-5.6505
EPS:
-0.8424
Net Cash Flow:
$-35.25M
1W Performance:
-8.11%
1M Performance:
+15.82%
6M Performance:
+0.21%
1Y Performance:
+176.74%
1-Day Range:
$4.70
$4.93
1-Week Range:
$4.60
$5.55
52-Week Range:
$1.50
$7.07
Opus Genetics Inc Stock (IRD) Company Profile
Name
Opus Genetics Inc
Sector
Industry
Phone
248-681-9815
Address
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
4.76 | 396.01M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-16-26 | Initiated | Oppenheimer | Outperform |
| Jan-20-26 | Initiated | BTIG Research | Buy |
| Dec-10-25 | Initiated | B. Riley Securities | Buy |
| Nov-25-25 | Initiated | Piper Sandler | Overweight |
| Oct-29-25 | Initiated | Wedbush | Outperform |
| Oct-16-25 | Initiated | Chardan Capital Markets | Buy |
| Apr-11-25 | Initiated | Craig Hallum | Buy |
| Nov-13-24 | Resumed | H.C. Wainwright | Buy |
View All
Opus Genetics Inc Stock (IRD) Latest News
Opus Genetics, Inc.(NasdaqCM: IRD) added to S&P Global BMI Index - marketscreener.com
IRD Should I Buy - Intellectia AI
Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified? - Yahoo Finance
Opus Genetics (IRD) CEO exercises 392K-share warrant in cashless deal - stocktitan.net
Form 8K Opus Genetics Inc For: 11 September By Investing.com - Investing.com Nigeria
Opus Genetics Updates Clinical Data Presentation for OPGx-BEST1 Phase 1/2 Trial - kalkinemedia.com
Opus Genetics Gene Therapy OPGx-BEST1 Safe, Shows Improvement in 4 of 5 Patients - Minichart
Opus Genetics Updates OPGx-BEST1 Trial Data and Outlook - TipRanks
Opus Genetics Inc - Reuters
Opus Genetics CEO George Magrath Executes Warrant for 392,157 Shares via Cashless Exercise - Kalkine Media
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Opus Genetics (NASDAQ: IRD) Plans Phase 3 Trial for OPGx-BEST1 in 2027 Following Promising Cohort 1 Results - Kalkine Media
Opus BEST1 and done? Gene therapy scores in rare eye diseases - BioWorld News
Opus Genetics: A Resounding Study Success Merits A Higher Valuation (NASDAQ:IRD) - Seeking Alpha
IRD Maintained by Wedbush -- Price Target Raised to $13.00 - GuruFocus
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $10 to $20 - Moomoo
Chardan Raises Price Target on Opus Genetics to $16 From $13, Keeps Buy Rating - marketscreener.com
Opus Genetics Stock Jumps 32% on Five-Patient Eye-Therapy Data—What IRD Must Prove Next - TechStock²
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Wedbush raises Opus Genetics stock price target on FDA alignment By Investing.com - Investing.com Nigeria
IRD Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Opus Genetics Shares Jump 30% as Low-Dose Gene Therapy Shows Vision Gains in Retinal Disease Trial - finance.biggo.com
Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy TrialSlideshow - Seeking Alpha
Opus Genetics Shares Rise After Reporting Vision Improvement in Phase 1/2 OPGx-BEST1 Trial - marketscreener.com
IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial - Yahoo Finance
Wedbush raises Opus Genetics stock price target on FDA alignment - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
IRD: OPGX-BEST1 gene therapy showed robust safety and efficacy, supporting phase III advancement - TradingView
IRD Reiterates by BTIG -- Price Target Maintained at $12.00 - GuruFocus
Why Opus Genetics (IRD) Stock Is Up Today - quiverquant.com
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Raises Target Price to $20 - Moomoo
Opus Genetics Reports Positive Phase 1/2 Data for Gene Therapy OPGx-BEST1 - Minichart
Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says - Benzinga
IRD: OPGX-BEST1 Phase 1/2 trial showed strong efficacy, safety, and FDA alignment for pivotal development - TradingView
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data, Targets Potential Phase 3 Dosing in 2027 - Yahoo Finance
IRD: OPGX-BEST1 gene therapy showed robust safety and functional gains, supporting pivotal trial advancement - TradingView
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving High - Benzinga
Opus Genetics Reveals Interim Phase 1/2 BIRD-1 Trial Outcomes for OPGx-BEST1 - Kalkine Media
IRD Stock Jumps As Traders Target Gene Therapy Catalyst - timothysykes.com
IRD Stock Eyes Webcast Catalyst As Gene Therapy Data Nears - StocksToTrade
IRD Maintained by Chardan Capital -- Price Target at $13.00 - GuruFocus
Opus Genetics Reports Positive Phase 1/2 Data for OPGx-BEST1 in BEST1-Related Retinal Disease - Eyewire+
Opus Genetics Reports Vision Improvement in Phase 1/2 OPGx-BEST1 Trial - marketscreener.com
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data - TipRanks
IRD Looks 1451.8% Overvalued on GF Value™ - GuruFocus
Opus Genetics reports positive low‑dose Cohort 1 OPGx-BEST1 Phase 1/2 data; advances to higher-dose Cohort 2 - TradingView
Opus Genetics Reports Positive Interim Phase 1/2 Results for OPGx-BEST1 in BEST1-Related Retinal Diseases - quiverquant.com
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 - Yahoo Finance
Opus Genetics, Inc. (NASDAQ: IRD) Share Price, IRD Stock News, IRD Share Price & Updates - Kalkine
Opus Genetics Director Cam Gallagher Exercises Warrant for 784,314 Shares, Enters 180-Day Lock-Up - Kalkine Media
Opus Genetics (IRD) director adds shares, accepts 180-day lock-up - Stock Titan
Opus Genetics Inc Stock (IRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):